Memory is preserved in older adults taking AT1 receptor blockers

Alzheimer's Research and Therapy

Volumn 9, Issue 1, 2017, Pages

  Ho, Jean K ^a   Nation, Daniel A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Angiotensin receptor blockers; Antihypertensive medication; Blood pressure; Memory

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SIZE; COGNITION; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POST HOC ANALYSIS; REY AUDITORY VERBAL LEARNING TEST; WHITE MATTER; ADVERSE DRUG REACTION; AGING; CAUSALITY; COMORBIDITY; DEMENTIA; DRUG EFFECTS; FRANCE; INCIDENCE; MEMORY DISORDER; PHYSIOLOGY; PREVALENCE; RECALL; RETROSPECTIVE STUDY; RISK FACTOR; TASK PERFORMANCE;

AGED; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIPSYCHOTIC AGENTS; CAUSALITY; COMORBIDITY; DEMENTIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MEMORY; MEMORY DISORDERS; MENTAL RECALL; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TASK PERFORMANCE AND ANALYSIS;

EID: 85018851970     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-017-0255-9     Document Type: Article

References (53)

1. Veglio F, Paglieri C, Rabbia F, Bisbocci D, Bergui M, Cerrato P. Hypertension and cerebrovascular damage. Atherosclerosis. 2009;205:331-41.
2. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101:181-9.
3. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 2002;33:1152-62.
4. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723-38.
5. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res. 2006;28:605-11.
6. Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7:686-98.
7. Christensen H. What cognitive changes can be expected with normal ageing? Aust N Z J Psychiatry. 2001;35:768-75.
8. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-8.
9. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:1683-9.
10. Waldstein SR, Rice SC, Thayer JF, Najjar SS, Scuteri A, Zonderman AB. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51:99-104.
11. Saxby BK, Harrington F, McKeith IG, Wesnes K, Ford GA. Effects of hypertension on attention, memory, and executive function in older adults. Health Psychol. 2003;22:587-91.
12. Waldstein SR. The relation of hypertension to cognitive function. Curr Dir Psychol Sci. 2003;12:9-12.
13. Nation D, Wierenga C, Delano-Wood L, Jak A, Delis D, Salmon D, et al. Elevated pulse pressure is associated with age-related decline in language ability. J Int Neuropsychol Soc. 2010;16:933-8.
14. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008;7:476-84.
15. Gentile MT, Poulet R, Di Pardo A, Cifelli G, Maffei A, Vecchione C, et al. β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging. 2009;30:222-8.
16. Langbaum JB, Chen K, Launer LJ, Fleisher AS, Lee W, Liu X, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012;33:827.e11-9.
17. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013;70:600-6.
18. Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, et al. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology. 2013;81:2024-7.
19. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke. 2003;34:594-9.
20. Fournier A, Oprisiu-Fournier R, Serot J, Godefroy O, Achard J, Faure S, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9:1413-31.
21. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;4, CD004034.
22. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312:801-5.
23. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-75.
24. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the Systolic Hypertension in the Elderly Program. Arch Intern Med. 1994;154:2154-60.
25. Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol. 2001;153:72-8.
26. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72:1720-6.
27. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72:1727-34.
28. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31:1073-82.
29. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003;17:781-5.
30. Hajjar I, Hart M, Chen Y, Mack W, Novak V, Chui CH, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc. 2013;61:194-201.
31. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201-9.
32. Furiya Y, Ryo M, Kawahara M, Kiriyama T, Morikawa M, Ueno S. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Alzheimers Dement. 2013;9:512-8.
33. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med. 2009;169:1195-202.
34. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-8.
35. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
36. Jack Jr CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685-91.
37. Christensen GE, Joshi SC, Miller MI. Volumetric transformation of brain anatomy. IEEE Trans Med Imaging. 1997;16:864-77.
38. Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inform Process Med Imaging. 2009;21:239-51.
39. Carmichael O, Mungas D, Beckett L, Harvey D, Farias ST, Reed B, et al. MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging. 2012;33:83-95.e2.
40. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7:108-14.
41. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.
42. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26:699-708.
43. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci. 2009;32:619-28.
44. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10:43-53.
45. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, et al. Angiotensin converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc. 2004;52:649-50.
46. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63:1324-5.
47. Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain. 2007;130:731-9.
48. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009;109:171-80.
49. Llorens-Cortes C, Mendelsohn FA. Organisation and functional role of the brain angiotensin system. J Renin Angiotensin Aldosterone Syst. 2002;3 Suppl 1:S39-48.
50. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881-900.
51. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110:843-8.
52. Nation DA, Ho J, Yew B. Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloid retention. J Alzheimers Dis. 2016;50:779-89.
53. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community. J Clin Hypertens. 2014;16:14-26.